EGCG ((-)-Epigallocatechin Gallate)
中文名称：(-)-表没食子儿茶素没食子酸酯
EGCG ((-)-Epigallocatechin Gallate)是从绿茶中分离的一种有效的抗氧化剂Polyphenol flavonoid。抑制telomerase和DNA methyltransferase， 阻滞EGF受体和HER-2受体的激活，抑制脂肪酸合成酶以及谷氨酸脱氢酶的活性。
-Epigallocatechin-gallate-chemical-structure-S2250.gif)
EGCG ((-)-Epigallocatechin Gallate) Chemical Structure
CAS: 989-51-5
客户使用Selleck的EGCG ((-)-Epigallocatechin Gallate)发表文献37篇
产品质控
EGCG ((-)-Epigallocatechin Gallate)相关产品
| 相关化合物库 | FDA药物库 天然产物库 凋亡分子化合物库 DNA损伤/ DNA修复化合物库 细胞周期化合物库 | 点击展开 |
|---|
相关信号通路图
Telomerase抑制剂选择性比较
细胞实验数据示例
| 细胞系 | 实验类型 | 给药浓度 | 孵育时间 | 活性描述 | 文献信息 |
|---|---|---|---|---|---|
| human MDA435/LCC6MDR cells | Function assay | 10 μM | 5 days | Modulation of P-gp (unknown origin) transfected in human MDA435/LCC6MDR cells assessed as reversible of paclitaxel resistance measured as IC50 for paclitaxel at 10 uM after 5 days by CellTiter 96 Aqueous assay, IC50=0.1226 μM | 25985195 |
| human Caco-2 cells | Growth inhibition assay | 25 μM | 6 days | Growth inhibition of human Caco-2 cells at 25 uM after 6 days | 18324763 |
| mouse 3T3 cells | Function assay | 1-20 μM | 12 h | Antimigratory activity against Swiss albino mouse 3T3 cells assessed as increase of cell numbers at 1 to 20 uM after 12 hrs by by scratch-wound assay | 21080642 |
| human Jurkat cells | Function assay | 10-55 μM | 24 h | Inhibition of TNFalpha-induced NF-kappaB activation in human Jurkat cells at 10 to 55 uM after 24 hrs by electrophoretic mobility shift assay | 21080642 |
| human Raji cells | Growth inhibition assay | 10 μM | 48 h | Growth inhibition against human Raji cells assessed as cell viability at 10 uM after 48 hrs by trypan blue based microscopic analysis in presence of superoxide dismutase | 21434603 |
| human PC3 cells | Proliferation assay | 10-100 μM | 48 h | Antiproliferative activity against human PC3 cells at 10 to 100 uM after 48 hrs by hemocytometric cell counting method | 23867167 |
| human A431 cells | Function assay | 100 μM | 12 h | Reduction of clustering of GFP-GPI in lipid rafts of human A431 cells at 100 uM after 12 hrs by confocal microscopic analysis | 24456004 |
| human SKBR3 cells | Function assay | 200μM | 30 mins | Downregulation of ErbB2 protein expression in human SKBR3 cells in serum free medium at 200 uM after 30 mins by immunofluorescence staining-based confocal microscopic analysis | 24456004 |
| human 293T cells | Function assay | 50 μM | 12 h | Inhibition of DYRK1A in human 293T cells assessed as reduction of GLI1 transcription activity at 50 uM after 12 hrs by dual-luciferase reporter gene assay | 22154664 |
| CHO cells | Cytotoxic assay | 48 h | Cytotoxicity against CHO cells expressing OATP1B3 haplotype 1 after 48 hrs by fluorescence based CellTiter-Glo assay, IC50=3.2 μM | 23327877 | |
| MDCK cells | Function assay | 4 days | Antiviral activity against influenza A virus (A/swine/OH/511445/2007(H1N1)) Oh7 infected in MDCK cells assessed as inhibition of viral replication after 4 days by quantitative RT-PCR, ED50=8.3 μM | 22115591 | |
| human HL60 cells | Proliferation assay | 3 days | Antiproliferative activity against human HL60 cells after 3 days, IC50=9.4 μM | 18693020 | |
| HSC-T6 cells | Function assay | 48 h | Antifibrotic activity against rat HSC-T6 cells assessed as inhibition of proliferation after 48 hrs by BrdU incorporation assay, IC50=9.9 μM | 21504848 | |
| mouse RAW264.7 cells | Function assay | 5 days | Inhibition of RANKL-induced osteoclastogenesis in mouse RAW264.7 cells assessed as decrease in TRAP-positive multi-nucleated cells after 5 days, IC50=29.8 μM | 21456521 | |
| human A431 cells | Proliferation assay | 48 h | Antiproliferative activity against human A431 cells overexpressing ErbB in serum-free medium assessed as cell viability after 48 hrs by WST-1 assay, EC50=38 μM | 24456004 | |
| human MDA-MB-231 cells | Proliferation assay | 24 h | Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay | 22459208 | |
| human HepG2 cells | Function assay | 24 h | Inhibition of oleic acid-induced triglyceride over-accumulation in human HepG2 cells incubated for 24 hrs relative to untreated control | 21824690 | |
| human HepG2 cells | Function assay | 24 h | Antioxidant activity in human HepG2 cells assessed as reduction of oleic acid-induced ROS generation incubated for 24 hrs by DHCF-DA based fluorimetric assay relative to untreated control | 21824690 | |
| human MDA-MB-231 cells | Proliferation assay | 24 h | Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay | 22459208 | |
| human K562 cells | Function assay | 24 h | Induction of 67 kDa laminin receptor expression in human K562 cells after 24 hrs by flow cytometry analysis | 21434603 | |
| human HL60 cells | Function assay | 24 h | Induction of 67 kDa laminin receptor expression in human HL60 cells after 24 hrs by flow cytometry analysis | 21434603 | |
| SH-SY5Y cells | Function assay | Neuroprotection against beta-amyloid peptide 1-42-induced toxicity in human SH-SY5Y cells assessed as lactate dehydrogenase release, EC50=0.03987 μM | 19138859 | ||
| Sf9 cells | Function assay | Inhibition of His6-tagged human recombinant DNMT1 expressed in insect Sf9 cells assessed as reduction in DNA methyltransferase activity using 5'-biotinylated 45-bp unmethylated or hemimethylated oligonucleotide substrates and [3H]-AdoMet by liquid scintillation counting method, IC50=0.5 μM | 25406944 | ||
| human U937 cells | Function assay | Inhibition of telomerase in human U937 cells, IC50=1 μM | 22413845 | ||
| human HeLa cells | Function assay | Inhibition of telomerase in human HeLa cells using 5'-AAT CCG TCG AGC AGA GTT-3' as substrate incubated for 15 mins prior to extension reaction followed by compound washout by spin-telomeric repeat amplification protocol, IC50=1.08 μM | 22413845 | ||
| mouse 3T3-L1 cells | Function assay | Inhibition of G6PD-mediated NADPH production in mouse 3T3-L1 cells, IC50=25 μM | 18313308 | ||
| HSC-T6 cells | Proliferation assay | Antiproliferative activity against rat HSC-T6 cells assessed as reduction in cell viability, IC50=29.8 μM | 25322455 | ||
| 点击查看更多细胞系数据 | |||||
生物活性
| 产品描述 | EGCG ((-)-Epigallocatechin Gallate)是从绿茶中分离的一种有效的抗氧化剂Polyphenol flavonoid。抑制telomerase和DNA methyltransferase， 阻滞EGF受体和HER-2受体的激活，抑制脂肪酸合成酶以及谷氨酸脱氢酶的活性。 | |||||
|---|---|---|---|---|---|---|
| 靶点 |
|
| 体外研究(In Vitro) | ||||
| 体外研究活性 | (-)-Epigallocatechin gallate在健康细胞中具有强效抗氧化作用，并降低氧化损伤，作为抗血管生成和抗肿瘤剂，也是肿瘤细胞对化疗应答的调节剂。(-)-Epigallocatechin gallate具有多种抗肿瘤作用，例如抗增殖，抗血管新生，阻断各种癌细胞转化，细胞周期阻滞和抑制肿瘤转移。(-)-Epigallocatechin gallate通过调节多个肿瘤相关的细胞信号通路（调节关键信号蛋白的表达水平，例如核因子-κB, MAPKs和激活蛋白-1，EGFR，IGF，COX-2）影响肿瘤基因的甲基化和配体与膜受体结合发挥抗肿瘤效果。[1] (-)-Epigallocatechin gallate具有免疫调节作用。多种类型的免疫细胞在先天的和适应性免疫系统中都会不同程度受到(-)-Epigallocatechin gallate的影响。在这些作用中，对T细胞的显著作用被反复证明，包括T细胞激活，增殖，分化和细胞因子产生。基于患有自身免疫疾病的动物模型的研究报道表明，绿茶/EGCG处理会使动物的病情好转。[2] (-)-Epigallocatechin gallate具有抗感染活性。(-)-Epigallocatechin gallate的以不同激活模式产生的抗病毒活性在很多种属的病毒中被证实，例如逆转录病毒，正粘病毒科和黄病毒科，还包括重要的人类病原细菌，如人类免疫缺陷病原体，甲型流感病毒和丙型肝炎病毒。[3] |
|||
|---|---|---|---|---|
| 实验图片 | 检测方法 | 检测指标 | 实验图片 | PMID |
| Western blot | β-catenin / p-AKT / Cyclin D1 p-MAPK / MAPK Notch1 / Notch2 |
|
28693189 | |
| Growth inhibiton assay | Cell proliferation Cell viability |
|
23525843 | |
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05758571 | Recruiting | Interstitial Pneumonia|Neoplasms Malignant |
Shandong Cancer Hospital and Institute |
January 5 2023 | Phase 1|Phase 2 |
| NCT03928847 | Completed | Idiopathic Pulmonary Fibrosis |
Hal Chapman|National Heart Lung and Blood Institute (NHLBI)|University of California San Francisco |
December 1 2017 | Early Phase 1 |
化学信息&溶解度
| 分子量 | 458.37 | 分子式 | C22H18O11 |
| CAS号 | 989-51-5 | SDF | Download EGCG ((-)-Epigallocatechin Gallate) SDF |
| 储存条件(自收到货起) | |||
|
体外溶解度 |
DMSO : 92 mg/mL ( (200.71 mM)； DMSO吸湿会降低化合物溶解度，请使用新开封DMSO) Ethanol : 92 mg/mL Water : 20 mg/mL |
摩尔浓度计算器 |
|
体内溶解度 现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂 |
动物体内配方计算器 | ||||
实验计算
动物体内配方计算器（澄清溶液）
第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
计算结果：
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；
体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH2O，混匀澄清。
体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。
注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
技术支持
在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。
如果有其他问题，请给我们留言。
* 必填项
